top of page

New toolkit informs of the risks of taking valproate during pregnancy

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new toolkit to ensure female patients are better informed about the risks of taking valproate medicines during pregnancy. Valproate is a treatment for epilepsy and bipolar disorder and is prescribed to thousands of women. It is associated with a risk of birth defects and developmental disorders in children born to women who take valproate during pregnancy.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page